24075-0411 : Conjupri 2.5 mg/2.5mg Oral Tablet


NDC: 24075-0411
Labeler: Cspc Ouyi Pharmaceutical Co. Ltd
Product Type: Human Prescription Drug
Drug Name:  Conjupri
Dosage Form: Oral Tablet
Application #: NDA212895
Rev. Date: 


Appearance:


Markings: OE;B47
Shapes:  Oval
Colors:  White
Size (mm): 12
Segments: * 2

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 2 indicates a scored pill which can be broken into 2 equal pieces.

NDC Package Codes:

  • 24075-0411-3: 2.5 MG IN 1 BOTTLE (24075‑0411‑3)
  • 24075-0411-5: 2.5 MG IN 1 BOTTLE (24075‑0411‑5)
  • 24075-0411-9: 2.5 MG IN 1 BOTTLE (24075‑0411‑9)

Active Ingredients:

  • Levamlodipine Maleate

Dosage Strength:

  • 2.5 mg/2.5mg

Inactive Ingredients:

  • Microcrystalline Cellulose
  • Betadex
  • Starch, Corn
  • Magnesium Stearate
  • Silicon Dioxide /

Related Products:

Based on records with the same trade name.
  • 24075-0410 Conjupri 1.25 mg/1.25mg Oral Tablet by Cspc Ouyi Pharmaceutical Co. Ltd
  • 24075-0412 Conjupri 5 mg/5mg Oral Tablet by Cspc Ouyi Pharmaceutical Co. Ltd
  • 24075-0413 Conjupri 5 mg/5mg Oral Tablet by Cspc Ouyi Pharmaceutical Co. Ltd
  • 66992-425 Conjupri 2.5 mg Oral Tablet by Wraser LLC
  • 66992-430 Conjupri 5 mg Oral Tablet by Wraser LLC
  • 69101-512 Conjupri 1.25 mg Oral Tablet by Burke Therapeutics, LLC
  • 69101-525 Conjupri 2.5 mg Oral Tablet by Burke Therapeutics, LLC
  • 69101-550 Conjupri 5 mg Oral Tablet by Burke Therapeutics, LLC

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 24075-0411 QR Code

< Prev: 24075-0410Next: 24075-0412 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.